Compare Remitly Global Inc (RELY) vs Tango Therapeutics Inc. (TNGX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Remitly Global Inc vs Tango Therapeutics Inc. — how do they compare? Remitly Global Inc trades at $23.48 (market cap $5.03B), while Tango Therapeutics Inc. trades at $22.23 (market cap $3.75B). The key difference: Remitly Global Inc is the larger of the two by market cap, and Remitly Global Inc is trading nearer its 52-week high, Tango Therapeutics Inc. nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Remitly Global Inc for 53 Days and Tango Therapeutics Inc. for 0 Days on average.
| RELY | TNGX | |
|---|---|---|
Market Cap | $5.03B | $3.75B |
Volume | 2,682,448 | 9,619,106 |
Sector | Technology | Health |
52-Week High | $26.92 | $32.90 |
52-Week Low | $12.20 | $7.50 |
Typical Hold Time | 53 Days | 0 Days |
Enterprise Value | $4.39B | $2.77B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
RELY trades at $23.49, showing modest daily movement with strong technical momentum. The company demonstrates accelerating revenue growth, reaching $1.64 billion in 2025 with improving profitability margins. Recent earnings consistently beat expectations, with Q2 2026 EPS of $0.93 significantly exceeding the $0.12 forecast. Analyst sentiment remains overwhelmingly positive with 92% buy ratings and a $30.50 consensus price target, representing 30% upside potential from current levels.
The outlook remains bullish given strong fundamentals and growth trajectory, though the stock faces risks from competitive pressures and potential market volatility. RELY's transition to profitability and expanding customer base to over 10 million active users supports continued upside, while elevated valuation multiples require sustained execution to justify current levels.
TNGX trades at $22.22, down 8.07% in the last session, reflecting negative investor reaction to recent earnings misses. The stock shows neutral technical signals with key support at $21 and resistance at $23. Fundamentally, the company maintains a high gross margin of 98.25% but faces significant losses with a net income margin of -229.92% and negative cash flow from operations. Recent news highlights institutional buying interest and upcoming clinical trial developments.
Despite strong analyst support with a $45.91 consensus price target (107% upside), TNGX faces substantial execution risks as a clinical-stage biotech. The company's heavy cash burn and lack of profitability require careful monitoring of pipeline progress. Investment appeal hinges on successful drug development outcomes rather than current financial metrics.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About Remitly Global Inc
Remitly Global Inc provides integrated financial services to immigrants, including helping customers send money internationally in a quick, reliable, and more cost-effective manner by leveraging digital channels. It supports cross-border transmissions across the globe. Its revenue is generated on transaction fees charged to customers and foreign exchange spreads between the foreign exchange rate offered to customers and the foreign exchange rate on the company's currency purchases.
Read more on RELY →About Tango Therapeutics Inc.
Tango Therapeutics, Inc. is a clinical-stage biotechnology company focused on precision oncology, developing cancer therapies based on the genetic principle of synthetic lethality, including its PRMT5 inhibitor program.
Read more on TNGX →
